Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Zawisza

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology

English

Related publications

P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology

English

P066 a Phase I Study of Apatinib Combined With Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology

English

P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)

Journal of Thoracic Oncology

English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology

English

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

Journal of Thoracic Oncology

English

P2.13-39 a Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination With Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

P1.01-14 Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis

Journal of Thoracic Oncology

English

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

Journal of Thoracic Oncology

English

OA05.07 IMpower132: PFS and Safety Results With 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Zawisza

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Related publications

P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women With Metastatic Non-Squamous NSCLC

P066 a Phase I Study of Apatinib Combined With Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC

P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

P2.13-39 a Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination With Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients

P1.01-14 Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

OA05.07 IMpower132: PFS and Safety Results With 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC